Plasmid DNA OVERVIEW PROCESS DEVELOPMENT CGMP MANUFACTURING PLASMID DNA VIRAL VECTOR CELL THERAPY QUALITY AND REGULATORY PROCESS VALIDATION AGC Biologics has been manufacturing plasmid DNA (pDNA) for over 10 years. We are experienced in both clinical and commercial pDNA manufacturing. AGC Biologics has expanded its capabilities by extending services in hosts and plasmids (low and high copy pDNA expression systems) via a robust toolbox in process development with scales of 1L to 10L. These processes can easily be scaled up to 1000L GMP manufacturing. pDNA can been used for diverse applications: DNA adjuvants and vaccines RNA drugs and vaccines Cell-free protein expression platforms Viral vector manufacturing, including for: Lentivirus Adeno-associated virus (AAV)-based therapeutics ABOUT CAPABILITIES RESOURCES FACILITIES NEWS & EVENTS LEGAL & COMPLIANCE CONTACT US Follow us on LinkedIn Follow us on Twitter Follow us on Facebook NEWS AGC Biologics Appoints Jean-Baptiste Agnus as Chief Business Officer AGC Biologics Expands pDNA and mRNA Manufacturing Capacity AGC Biologics Announces the Groundbreaking of its New Facility at its Copenhagen, Denmark Site AGC Biologics Appoints Tony Fraij as the new General Manager/Site Head of the Longmont, Colorado Site AGC Biologics Acquires Commercial Facility, Expanding Cell & Gene Therapy Global Service Offerings EVENTS Cell & Gene Meeting on the Mesa, October 12-14, 2021 AGC Biologics is Attending BIO Asia-Taiwan July 23-26, 2021 Presenting Our Biological and Cell & Gene Therapy Capabilities AGC Biologics is Attending ASGCT May 11-14, 2021 and Presenting Our Scalable LVV Production Process and Large-Scale AAV Manufacturing Development Data AGC Biologics is Attending Meeting on the Med, April 6-9, 2021 FACILITIES SEATTLE, WASHINGTON (Headquarters) BOULDER, COLORADO LONGMONT, COLORADO COPENHAGEN, DENMARK HEIDELBERG, GERMANY MILAN, ITALY CHIBA, JAPAN ©2021 AGC Biologics. All Rights Reserved. Website Privacy Policy